When considering the efficacy of immune checkpoint inhibitors, promising clinical responses have been observed with anti-PD-1 and anti-CTLA-4 blockade in lung cancer and melanoma [42-45], both of which are associated with the highest cancer mutation rates [8, 35]. Here, CTLA4 is linked to lung carcinoma.